Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
3/24/2026, 12:00:00 AM
During an investor webinar, Alnylam highlighted strong commercial momentum for its drug AMVUTTRA and reiterated its 2026 TTR revenue guidance of $4.4 billion to $4.7 billion. The company also announced strategic collaborations with Viz.ai and the American Heart Association to accelerate patient diagnosis.
Korean Translation
투자자 웨비나에서 심장질환 치료제 AMVUTTRA의 강력한 상업적 모멘텀을 강조하고 2026년 TTR(트랜스티레틴) 관련 매출 가이던스 44억~47억 달러를 재확인함. 또한 환자 진단을 가속화하기 위해 Viz.ai 및 미국심장협회(AHA)와의 전략적 협력을 발표함.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
CME Group Inc (CME) · Other
CME Group will expand regulated cryptocurrency futures and options trading to 24/7 starting on 2026-05-29, pending regulatory review, scheduled.
5/29/2026, 12:00:00 AM
Dell Technologies Inc (DELL) · Earnings Release
Dell Technologies is scheduled to report its fiscal Q1 2027 earnings on May 28, 2026. Since earnings reports typically drive price movements exceeding 5%, significant volatility is scheduled.
5/28/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
ONEOK 2026 annual meeting of shareholders on May 20, 2026, is estimated to have a price impact of at least 1% and is scheduled.
5/20/2026, 12:00:00 AM
Keysight Technologies Inc (KEYS) · Earnings Release
Keysight Technologies' fiscal second-quarter 2026 earnings report is scheduled for May 19, 2026; a price movement of 5% or more is expected.
5/19/2026, 12:00:00 AM